Literature DB >> 17202279

Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.

Barbara D Alexander1, Terry C Byrne, Kelly L Smith, Kimberly E Hanson, Kevin J Anstrom, John R Perfect, L Barth Reller.   

Abstract

To assess their utility for antifungal susceptibility testing in our clinical laboratory, the Etest and Sensititre methods were compared with the Clinical and Laboratory Standards Institute (CLSI) M27-A2 reference broth microdilution method. Fluconazole (FL), itraconazole (I), voriconazole (V), posaconazole (P), flucytosine (FC), caspofungin (C), and amphotericin B (A) were tested with 212 Candida isolates. Reference MICs were determined after 48 h of incubation, and Etest and Sensititre MICs were determined after 24 h and 48 h of incubation. Overall, excellent essential agreement (EA) between the reference and test methods was observed for Etest (95%) and Sensititre (91%). Etest showed an >or=92% EA for MICs for all drugs tested; Sensititre showed a >or=92% EA for MICs for I, FC, A, and C but 82% for FL and 85% for V. The overall categorical agreement (CA) was 90% for Etest and 88% for Sensititre; minor errors accounted for the majority of all categorical errors for both systems. Categorical agreement was lowest for Candida glabrata and Candida tropicalis with both test systems. Etest and Sensititre provided better CA at 24 h compared to 48 h for C. glabrata; however, CA for C. glabrata was <80% for FL with both test systems despite MIC determination at 24 h. Agreement between technologists for both methods was >or=98% for each agent against all organisms tested. Overall, Etest and Sensititre methods compared favorably with the CLSI reference method for determining the susceptibility of Candida. However, further evaluation of their performance for determining the MICs of azoles, particularly for C. glabrata, is warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202279      PMCID: PMC1829106          DOI: 10.1128/JCM.01840-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes.

Authors:  A Schoofs; F C Odds; R Colebunders; M Ieven; L Wouters; H Goossens
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp.

Authors:  Charles R Sims; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; Luis Ostrosky-Zeichner
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

3.  Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole.

Authors:  Barbara D Alexander; Wiley A Schell; Jackie L Miller; Gwynn D Long; John R Perfect
Journal:  Transplantation       Date:  2005-09-27       Impact factor: 4.939

4.  Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.

Authors:  Annemarie Borst; Maria T Raimer; David W Warnock; Christine J Morrison; Beth A Arthington-Skaggs
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

5.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

6.  The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents.

Authors:  D Sanglard; F Ischer; D Calabrese; P A Majcherczyk; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

7.  Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.

Authors:  Maurizio Sanguinetti; Brunella Posteraro; Barbara Fiori; Stefania Ranno; Riccardo Torelli; Giovanni Fadda
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

8.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

Authors:  M B Edmond; S E Wallace; D K McClish; M A Pfaller; R N Jones; R P Wenzel
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

9.  Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.

Authors:  A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; S Killian; H A Norris; M A Ghannoum
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.

Authors:  Jo-Anne H van Burik; Voravit Ratanatharathorn; Daniel E Stepan; Carole B Miller; Jeffrey H Lipton; David H Vesole; Nancy Bunin; Donna A Wall; John W Hiemenz; Yoichi Satoi; Jeanette M Lee; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2004-10-27       Impact factor: 9.079

View more
  40 in total

1.  Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia.

Authors:  Emilia Cantón; Javier Pemán; Guillermo Quindós; Elena Eraso; Ilargi Miranda-Zapico; María Álvarez; Paloma Merino; Isolina Campos-Herrero; Francesc Marco; Elia Gomez G de la Pedrosa; Genoveva Yagüe; Remedios Guna; Carmen Rubio; Consuelo Miranda; Carmen Pazos; David Velasco
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods.

Authors:  Nuri Kiraz; Ilknur Dag; Mustafa Yamac; Abdurrahman Kiremitci; Nilgun Kasifoglu; Yurdanur Akgun
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

3.  Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.

Authors:  M A Pfaller; V Chaturvedi; D J Diekema; M A Ghannoum; N M Holliday; S B Killian; C C Knapp; S A Messer; A Miskov; R Ramani
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

4.  Comparison of commercial methods and the CLSI broth microdilution to determine the antifungal susceptibility of Candida parapsilosis complex bloodstream isolates from three health institutions in Rio de Janeiro, Brazil.

Authors:  Maria Helena G Figueiredo-Carvalho; Leonardo S Barbedo; Manoel M E Oliveira; Fábio Brito-Santos; Rodrigo Almeida-Paes; Rosely M Zancopé-Oliveira
Journal:  Mycopathologia       Date:  2014-06-22       Impact factor: 2.574

5.  Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods.

Authors:  Nuri Kiraz; Ilknur Dag; Mustafa Yamac; Abdurrahman Kiremitci; Nilgun Kasifoglu; Yasemin Oz
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

6.  Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010.

Authors:  Yu-Tsung Huang; Chia-Ying Liu; Chun-Hsing Liao; Kuei-Pin Chung; Wang-Huei Sheng; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

7.  Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive Candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and Etest methods.

Authors:  N Bourgeois; L Dehandschoewercker; S Bertout; P-J Bousquet; P Rispail; L Lachaud
Journal:  J Clin Microbiol       Date:  2009-11-04       Impact factor: 5.948

8.  Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods.

Authors:  Jong Hee Shin; Mi-Na Kim; Sook Jin Jang; Min Young Ju; Soo Hyun Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

9.  Change in species distribution and antifungal susceptibility of candidemias in an intensive care unit of a university hospital (10-year experience).

Authors:  Bilgul Mete; Esra Yerlikaya Zerdali; Gokhan Aygun; Nese Saltoglu; Ilker Inanc Balkan; Ridvan Karaali; Sibel Yildiz Kaya; Berna Karaismailoglu; Abdurrahman Kaya; Seval Urkmez; Gunay Can; Fehmi Tabak; Recep Ozturk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-09-15       Impact factor: 3.267

10.  Evaluating the resistance to posaconazole by E-test and CLSI broth microdilution methodologies of Candida spp. and pathogenic moulds.

Authors:  R Araujo; S Costa-de-Oliveira; I Coutinho; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.